Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Morphosys Ag ADR
(NQ:
MOR
)
18.64
-0.05 (-0.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Morphosys Ag ADR
< Previous
1
2
3
4
Next >
MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
June 04, 2021
Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
Product Safety
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
June 02, 2021
MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation...
From
MorphoSys AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
MorphoSys to Acquire Constellation Pharmaceuticals
June 02, 2021
From
MorphoSys AG
Via
Business Wire
MorphoSys To Participate in UBS Global Healthcare Conference
May 21, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a...
From
MorphoSys AG
Via
AccessWire
MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting
May 19, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 19, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new data from the tafasitamab (Monjuvi(R)) development program will be presented at the...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
Product Safety
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma
May 11, 2021
PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma
May 11, 2021
From
Incyte
Via
Business Wire
MorphoSys AG Reports First Quarter 2021 Results
May 05, 2021
- MonjuviU.S. net product sales of € 12.9 million (US$ 15.5 million) - Tremfya royalties of € 11.6 million - Reaffirming group revenue guidance of € 150 to € 200 million - Conference call and webcast...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
DGAP-News: Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021
April 28, 2021
Conference Call Alert Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 MUNICH, GERMANY / ACCESSWIRE / April 28, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ: MOR), a...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
April 19, 2021
PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / April 19, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the first...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
April 19, 2021
From
Incyte and MorphoSys AG
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.